Invivyd (IVVD) News Today $0.63 +0.02 (+2.79%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Invivyd (NASDAQ:IVVD) Earns Buy Rating from HC WainwrightMarch 28 at 2:53 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Invivyd in a report on Wednesday.March 27 at 8:26 AM | marketbeat.comInvivyd Appoints Ajay Royan to Board of DirectorsMarch 26 at 4:58 PM | tipranks.comInvivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of DirectorsMarch 26 at 4:15 PM | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Invivyd (NASDAQ:IVVD)March 22, 2025 | americanbankingnews.comInvivyd's (IVVD) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Invivyd in a report on Thursday.March 21, 2025 | marketbeat.comInvivyd reports FY24 EPS ($1.43) vs. ($1.81) last yearMarch 21, 2025 | markets.businessinsider.comInvivyd (NASDAQ:IVVD) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPSInvivyd (NASDAQ:IVVD - Get Free Report) released its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10.March 21, 2025 | marketbeat.comInvivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsMarch 20, 2025 | globenewswire.comInvivyd (IVVD) Projected to Post Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comAre Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?March 12, 2025 | msn.comInvivyd (NASDAQ:IVVD) Receives Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Wednesday.March 6, 2025 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest UpdateInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 8,510,000 shares, a growth of 28.5% from the January 31st total of 6,620,000 shares. Currently, 11.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 13,950,000 shares, the days-to-cover ratio is presently 0.6 days.March 6, 2025 | marketbeat.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | finanznachrichten.deInvivyd announces in vitro neutralization data for PEMGARDAMarch 5, 2025 | markets.businessinsider.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | globenewswire.comInvivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 AntibodyMarch 4, 2025 | finance.yahoo.comWhy Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025March 2, 2025 | msn.comH.C. Wainwright Reaffirms Their Buy Rating on Invivyd (IVVD)February 25, 2025 | markets.businessinsider.comInvivyd, Inc.: FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart)February 25, 2025 | finanznachrichten.deInvivyd Shares Down as Regulators Decline Expanded Use for Covid-19 TreatmentFebruary 25, 2025 | marketwatch.comInvivyd says FDA declines request to expand existing EUA of PEMGARDAFebruary 25, 2025 | markets.businessinsider.comInvivyd shares drop as FDA declines company's COVID-19 treatment EUA expansionFebruary 25, 2025 | msn.comInvivyd news ‘disappointing’ but not in model, says H.C. WainwrightFebruary 25, 2025 | markets.businessinsider.comInvivyd's (IVVD) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research report on Monday.February 24, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $9.00 target price on shares of Invivyd in a research note on Monday.February 24, 2025 | marketbeat.comFDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised PatientsFebruary 24, 2025 | globenewswire.comWhy Invivyd, Inc. (IVVD) Is Soaring This Year So FarFebruary 19, 2025 | msn.comInvivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short InterestInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 6,620,000 shares, a growth of 5.2% from the January 15th total of 6,290,000 shares. Approximately 8.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 12,710,000 shares, the short-interest ratio is presently 0.5 days.February 17, 2025 | marketbeat.comInvivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025February 10, 2025 | globenewswire.comThis Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.February 6, 2025 | msn.comInvestors Buy High Volume of Call Options on Invivyd (NASDAQ:IVVD)Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw some unusual options trading activity on Thursday. Investors bought 2,267 call options on the company. This is an increase of approximately 463% compared to the average daily volume of 403 call options.February 6, 2025 | marketbeat.comHC Wainwright Has Negative View of Invivyd FY2024 EarningsInvivyd, Inc. (NASDAQ:IVVD - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Invivyd in a research note issued on Tuesday, February 4th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.64) per share for the year, doFebruary 6, 2025 | marketbeat.comInvivyd partners with football coach Jim Harbaugh for COVID-19 risk awarenessFebruary 6, 2025 | markets.businessinsider.comInvivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A ColdFebruary 5, 2025 | globenewswire.comHC Wainwright Reiterates Buy Rating for Invivyd (NASDAQ:IVVD)HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Invivyd in a research note on Tuesday.February 5, 2025 | marketbeat.comI See The Bull Case For Invivyd, But I'm Not Married To ItFebruary 4, 2025 | seekingalpha.comH.C. Wainwright maintains Buy rating on Invivyd stock at $10 targetFebruary 4, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD)HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research report on Tuesday.February 4, 2025 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short InterestInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 31st total of 3,670,000 shares. Based on an average daily volume of 958,500 shares, the days-to-cover ratio is presently 4.2 days. Currently, 5.3% of the shares of the stock are sold short.February 4, 2025 | marketbeat.comWhy Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comPenny Stocks To Research - February 03rdInvivyd, Society Pass, HCW Biologics, U.S. Energy, and BigBear.ai are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are typically low-priced, speculative securities of small companies that trade for less than $5 per share. These stocks are often hFebruary 3, 2025 | marketbeat.comInvivyd provides preliminary Q4 resultsFebruary 3, 2025 | markets.businessinsider.comInvivyd announces Phase 1/2 data for VYD2311February 3, 2025 | markets.businessinsider.comInvivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term ProfitabilityFebruary 3, 2025 | globenewswire.comAdagio Therapeutics stock hits 52-week low at $0.38January 30, 2025 | msn.comWe Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) SoonJanuary 30, 2025 | uk.finance.yahoo.comInvivyd announces submission to FDA of updated analysis of pemivibartJanuary 27, 2025 | markets.businessinsider.comD. Boral Capital Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)D. Boral Capital reiterated a "buy" rating and set a $9.00 target price on shares of Invivyd in a research report on Monday.January 27, 2025 | marketbeat.comInvivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised PatientsJanuary 27, 2025 | globenewswire.com Remove Ads Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Media Mentions By Week IVVD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVVD News Sentiment▼0.630.78▲Average Medical News Sentiment IVVD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVVD Articles This Week▼92▲IVVD Articles Average Week Remove Ads Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ESPR News Today TKNO News Today TSHA News Today BNTC News Today AMLX News Today ATYR News Today CMPX News Today AQST News Today TECX News Today ATAI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVVD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Trump Secretly Pumping Up Elon’s New AI Venture?President Trump just bought a Tesla - right in front of the White House. But what most investors don't real...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVVD Stock Free IVVD Stock Alerts